回复 Aljabali 等人对“阿巴斯等人研究的评论：nusinersen 在治疗脊髓性肌萎缩症中的安全性和疗效：随机对照试验的系统评价和荟萃分析。2022 年，，213”
Reply to Aljabali et al. Comment on "Abbas et al. The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2022, , 213".
机构信息
Department of Medicine, McLaren Health Care, Flint, MI 48532, USA.
Department of Medicine, Michigan State University, East Lansing, MI 48532, USA.
出版信息
Medicina (Kaunas). 2022 Jun 13;58(6):793. doi: 10.3390/medicina58060793.
Abstract
We appreciate Ahmed Sami Aljabali and his colleagues for their interest and comments [...].
摘要
我们感谢艾哈迈德·萨米·阿尔贾巴里（Ahmed Sami Aljabali）及其同事的关注和评论[... ]。
相似文献
1
Reply to Aljabali et al. Comment on "Abbas et al. The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2022, , 213".回复 Aljabali 等人对“阿巴斯等人研究的评论：nusinersen 在治疗脊髓性肌萎缩症中的安全性和疗效：随机对照试验的系统评价和荟萃分析。2022 年，，213”
Medicina (Kaunas). 2022 Jun 13;58(6):793. doi: 10.3390/medicina58060793.
2
Comment on Abbas et al. The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2022, , 213.评 Abbas 等人的研究：nusinersen 治疗脊髓性肌萎缩症的安全性和疗效：随机对照试验的系统评价和荟萃分析。2022 年， ，213 页。
Medicina (Kaunas). 2022 Jun 6;58(6):766. doi: 10.3390/medicina58060766.
3
The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.《依库珠单抗治疗视神经脊髓炎谱系疾病的有效性和安全性的 Meta 分析》
Medicina (Kaunas). 2022 Feb 1;58(2):213. doi: 10.3390/medicina58020213.
4
Current evidence for treatment with nusinersen for spinal muscular atrophy: a systematic review.目前使用 nusinersen 治疗脊髓性肌萎缩症的证据：系统评价。
Acta Neurol Belg. 2019 Dec;119(4):523-533. doi: 10.1007/s13760-019-01199-z. Epub 2019 Aug 6.
5
An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials.七项临床试验中接受 nusinersen 治疗的有症状脊髓性肌萎缩症（SMA）婴儿和儿童的综合安全性分析。
CNS Drugs. 2019 Sep;33(9):919-932. doi: 10.1007/s40263-019-00656-w.
6
Nusinersen: A Treatment for Spinal Muscular Atrophy.依库珠单抗：治疗脊髓性肌萎缩症的一种方法。
Ann Pharmacother. 2019 Jan;53(1):61-69. doi: 10.1177/1060028018789956. Epub 2018 Jul 16.
7
The light at the end of the tunnel gets vivid for spinal muscular atrophy: An Editorial Highlight for "Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy" on page 650.脊髓性肌萎缩症的隧道尽头之光变得鲜明：一篇社论亮点，内容为“用诺西那生钠治疗脊髓性肌萎缩症患者的脑脊液蛋白质组学分析”，刊登在第 650 页。
J Neurochem. 2020 Jun;153(5):545-548. doi: 10.1111/jnc.14976. Epub 2020 Mar 3.
8
Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study.用nusinersen 治疗婴儿型脊肌萎缩症：2 期、开放标签、多中心、剂量递增研究的最终报告。
Lancet Child Adolesc Health. 2021 Jul;5(7):491-500. doi: 10.1016/S2352-4642(21)00100-0. Epub 2021 Jun 3.
9
Nusinersen (Spinraza) for spinal muscular atrophy.用于脊髓性肌萎缩症的诺西那生（Spinraza）
Med Lett Drugs Ther. 2017 Mar 27;59(1517):50-52.
10
Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience.脊髓性肌萎缩症患儿鞘内注射：诺西那生临床试验经验
J Child Neurol. 2016 Jun;31(7):899-906. doi: 10.1177/0883073815627882. Epub 2016 Jan 27.
本文引用的文献
1
Comment on Abbas et al. The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2022, , 213.评 Abbas 等人的研究：nusinersen 治疗脊髓性肌萎缩症的安全性和疗效：随机对照试验的系统评价和荟萃分析。2022 年， ，213 页。
Medicina (Kaunas). 2022 Jun 6;58(6):766. doi: 10.3390/medicina58060766.
2
Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data.脊髓性肌萎缩症（SMA）患者接受 nusinersen、onasemnogene abeparvovec、risdiplam 或联合治疗的中、长期（至少 12 个月）随访：真实世界研究数据的系统评价。
Eur J Paediatr Neurol. 2022 Jul;39:1-10. doi: 10.1016/j.ejpn.2022.04.006. Epub 2022 Apr 30.
3
The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.《依库珠单抗治疗视神经脊髓炎谱系疾病的有效性和安全性的 Meta 分析》
Medicina (Kaunas). 2022 Feb 1;58(2):213. doi: 10.3390/medicina58020213.
4
Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study.依库珠单抗治疗脊髓性肌萎缩症的安全性和有效性：EMBRACE 研究。
Muscle Nerve. 2021 May;63(5):668-677. doi: 10.1002/mus.27187. Epub 2021 Feb 16.
5
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.依库珠单抗治疗晚发性脊髓性肌萎缩症的疗效观察：一项随机、双盲、安慰剂对照 3 期试验
N Engl J Med. 2018 Feb 15;378(7):625-635. doi: 10.1056/NEJMoa1710504.
6
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.依库珠单抗治疗婴儿型脊髓性肌萎缩症的疗效观察
N Engl J Med. 2017 Nov 2;377(18):1723-1732. doi: 10.1056/NEJMoa1702752.
Zotero 插件